
In February 2001, the journal Science
published two scientific papers that, for the first time, described
parts of the newly sequenced human genome. Ten years later, the journal
has dedicated the month of February to a
special series of literature about one of the most celebrated scientific breakthroughs our time.
It’s
a fitting time to discuss genomics. The field has attracted an
unprecedented array of entrepreneurial activity and venture capital, but
it’s promise has lost a little luster to an array of technical and
logistical challenges. Granted, most scientists hadn’t foreseen
practical findings in just a decade, but the business case for
sequencing companies is getting slightly more challenging. Clinical
results do not yet exist, and the greater challenge of proteomics is
considered by many the realm of study where a true understanding of
systems biology lies.
The Science
articles reflect the mixture of satisfaction and warning. National
Institutes of Health Director Francis S. Collins wrote about how
genomics is now beginning to
impact real people:
“When the draft sequence of the human genome was published in February 2001, Nature and Science
featured human faces on their covers. As striking as these images were,
they could be seen as more art than science, because systematic
genome-wide sequencing had yet to be applied to individuals for medical
purposes. What a difference a decade makes. Real faces are now appearing
that demonstrate the medical value of comprehensive genome sequencing.”
Collins
goes on to describes a 6-year-old Wisconsin boy who until recently
suffered from a poorly understand inflammatory condition of the bowels. A
whole genome analysis was performed. Researchers identified a genetic
mutation that eventually led to an experimental but potentially
successful treatment.
Even as Eric Green, director of the National Human Genome Research Institute, is counseling scientists
not to expect too much too soon
from genomic mapping breakthroughs, Collins message is an auspicious
one. Most researchers are still confident that the golden age of
genomics will soon be upon us.
But in the same issue of Science, genomics pioneer J. Craig Venter
strikes a cautionary tone.
Although sequencing techniques are constantly evolving and improving,
most cost-effective, or “cheap”, sequencing efforts fall far short of
the techniques required to obtain the full diploid human genome sequence
of 3 billion base pairs. As recently as 2007, he writes that sort of
comprehensive effort required nine months. A period of months is a vast
improvement over the four years it took Venter’s team to sequence
influenza, the first living species to be decoded. But even today, most
sequencing technologies produce much shorter sequences from much smaller
DNA fragments.
Sequencing
shortcomings might not be as problematic, Venter writes, but for the
fact that we lack a library of standardized human phenotypes against
which clinical trials and predictive DNA analysis can be performed. The
result, he says, is a gap between expectations and reality that is
likely to persist until we improve DNA data analysis:
“Although
many ‘genome’ companies and researchers are promoting personal genomics
for medicine and/or life choices, regulation of data quality and
standards is lacking, which has made deceptive marketing a reality in
some instances. We have sequence and genetic data quality that is
suitable for some scientific analyses but no standards adequate for
clinical practice or even for informing individuals of results that
exist. “
Venter, the 1998 R&D Magazine
Innovator of the Year, is no doubt aware that lack of standardization
does not indicate stagnation: development in sequencing technologies
will continue as long as potential benefits exist. Researchers are
inclined to look ahead. In the same issue of Science, the
prospect of whole population genetics
and the ability to target and track disease mutations is discussed,
even though we don’t yet have the tools to accomplish such wide-scale or
high-throughput analyses.
Both
Collins and Venter are likely aware of efforts in areas like
metabolomics and proteomics that may be complimentary to a better
understanding of the human genome. And as soon as real and positive
results emerge like the young boy cited by Collins, the push will be on
for standardization, clinical transitions, and, hopefully, universal
accessibility.